Jason Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Chen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Dat Ngo
Department of Pharmacy, City of Hope, Duarte, USA
13 shared publicationsDongyun Yang
Department of Computational and Quantitative Medicine, Division of Biostatistics Core, City of Hope, Duarte, USA
5 shared publications- Ryotaro Nakamura
Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA
5 shared publications Guido Marcucci
Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California USA
4 shared publications- Haris Ali
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
4 shared publications Stephen J. Forman
Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California USA
4 shared publications
Latest Publications
- 4 February 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (4) , 555-557
Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience
- 4 February 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (4) , 555-557
Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience
- Open Access
- 15 October 2024
- Published by Springer Nature in Research Square
Belumosudil for the Treatment of Chronic Graft-versus-Host Disease: A Single Center Real-World Experience
Chronic graft-versus host disease (cGVHD) remains a major complication post-allogeneic stem cell transplantation (HCT). Belumosudil, a ROCK2 inhibitor was approved for cGVHD with 2–5 prior lines of therapy. We retrospectively analyzed 45 patients who received belumosudil at City of Hope Medical Center. Prior to belumosudil, the median age was 59 yrs with 3 prior lines of therapy (range 1–6). GVHD severity was predominantly moderate (37.8%) and severe (46.7%). Many patients had a prior history of ruxolitinib (71.1%), with concurrent use of belumosudil occurring in 51.1% of patients. ORR at 6-months and 12 months were 31.1% and 33.4% respectively. The best ORR at any point during belumosudil was 46.7% (CR 6.7% + PR 40%) and median FFS was 11.2 months. Infection occurred in 42% of patients, with 27% of patients requiring hospitalization to manage infection. Patients with concurrent ruxolitinib had higher infection rates (60.9% vs. 22;7%, p = 0.0156) and hospitalization (47.8% vs. 4.5%, p = 0.0017). Most infections were viral and considered mild requiring no hospitalization to manage the infection. Real-world experience with belumosudil supports the use in the treatment of cGVHD based on the ORR, promising FFS, and good tolerability in patients who have progressed on multiple prior lines of therapy.
- 15 October 2024
- Published by Springer Nature in Research Square
Open AccessBelumosudil for the Treatment of Chronic Graft-versus-Host Disease: A Single Center Real-World Experience
Chronic graft-versus host disease (cGVHD) remains a major complication post-allogeneic stem cell transplantation (HCT). Belumosudil, a ROCK2 inhibitor was approved for cGVHD with 2–5 prior lines of therapy. We retrospectively analyzed 45 patients who received belumosudil at City of Hope Medical Center. Prior to belumosudil, the median age was 59 yrs with 3 prior lines of therapy (range 1–6). GVHD severity was predominantly moderate (37.8%) and severe (46.7%). Many patients had a prior history of ruxolitinib (71.1%), with concurrent use of belumosudil occurring in 51.1% of patients. ORR at 6-months and 12 months were 31.1% and 33.4% respectively. The best ORR at any point during belumosudil was 46.7% (CR 6.7% + PR 40%) and median FFS was 11.2 months. Infection occurred in 42% of patients, with 27% of patients requiring hospitalization to manage infection. Patients with concurrent ruxolitinib had higher infection rates (60.9% vs. 22;7%, p = 0.0156) and hospitalization (47.8% vs. 4.5%, p = 0.0017). Most infections were viral and considered mild requiring no hospitalization to manage the infection. Real-world experience with belumosudil supports the use in the treatment of cGVHD based on the ORR, promising FFS, and good tolerability in patients who have progressed on multiple prior lines of therapy.
- 28 May 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (9) , 1680-1690
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post‐HCT, but published clinical experience is primarily with the first‐generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second‐generation TKI (2G‐TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty‐six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G‐TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G‐TKI: 576.0 days (range, 72–921) versus 254.5 days (range, 3–2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5‐year overall survival and progression‐free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post‐HCT TKI maintenance in a large real‐world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common.
- 28 May 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (9) , 1680-1690
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post‐HCT, but published clinical experience is primarily with the first‐generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second‐generation TKI (2G‐TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty‐six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G‐TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G‐TKI: 576.0 days (range, 72–921) versus 254.5 days (range, 3–2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5‐year overall survival and progression‐free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post‐HCT TKI maintenance in a large real‐world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common.
- 27 May 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (8) , 1636-1639
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia
Improved first progression-free survival following allogeneic hematopoietic cell transplantation relapse with the use of immunotherapy.
- 27 May 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (8) , 1636-1639
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia
Improved first progression-free survival following allogeneic hematopoietic cell transplantation relapse with the use of immunotherapy.
- 2 January 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (1) , 12-16
Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients
Purpose: This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients. Methods: One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included. Results: Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826). Conclusion and relevance: Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.
- 2 January 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (1) , 12-16
Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients
Purpose: This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients. Methods: One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included. Results: Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826). Conclusion and relevance: Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.
- Open Access
- 25 August 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 19 (7) , 460-464
Preventing Potential Patient Harm Through Clinical Content Interventions During Oncology Clinical Trial Implementation
Objectives: Clinical trial documents are complex and may have inconsistencies, leading to potential site implementation errors and may compromise participant safety. This study characterizes the frequency and type of administrative and potential patient safety interventions (PPSIs) made during the review of oncology trial documents for clinical trial implementation by centralized clinical content specialists. Methods: A dedicated group of centralized clinical content specialists reviewed trial documents, including the protocol, laboratory manual, and pharmacy/cellular therapy manual, and collected intervention data over a 1-year period. Each trial was categorized by study phase and sponsor type, and multiple interventions could be identified per trial. Interventions were deemed administrative or PPSIs, with PPSIs further subcategorized as medication, laboratory, procedure related, or other. Results: Of 585 clinical trials reviewed, 269 (46%) required intervention(s). Among 1001 interventions, 171 (17.1%) were PPSIs. Most PPSIs were medication related (45.6%), with drug dosing interventions most frequently identified (53.8%). Phase 1 trials had the highest proportion of PPSIs (0.35:1) and administrative interventions (2:1) per trial compared with all other phases. Investigator-initiated trials saw the highest proportion of PPSIs per trial (0.44:1) of all sponsor types. Conclusions: This study demonstrates a gap in patient safety when assessing trial documents for clinical trial implementation. One solution to address this gap is the utilization of a centralized team of clinical specialists to preemptively review trial documents, thereby enhancing patient safety during clinical trial conduct.
- 25 August 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 19 (7) , 460-464
Open AccessPreventing Potential Patient Harm Through Clinical Content Interventions During Oncology Clinical Trial Implementation
Objectives: Clinical trial documents are complex and may have inconsistencies, leading to potential site implementation errors and may compromise participant safety. This study characterizes the frequency and type of administrative and potential patient safety interventions (PPSIs) made during the review of oncology trial documents for clinical trial implementation by centralized clinical content specialists. Methods: A dedicated group of centralized clinical content specialists reviewed trial documents, including the protocol, laboratory manual, and pharmacy/cellular therapy manual, and collected intervention data over a 1-year period. Each trial was categorized by study phase and sponsor type, and multiple interventions could be identified per trial. Interventions were deemed administrative or PPSIs, with PPSIs further subcategorized as medication, laboratory, procedure related, or other. Results: Of 585 clinical trials reviewed, 269 (46%) required intervention(s). Among 1001 interventions, 171 (17.1%) were PPSIs. Most PPSIs were medication related (45.6%), with drug dosing interventions most frequently identified (53.8%). Phase 1 trials had the highest proportion of PPSIs (0.35:1) and administrative interventions (2:1) per trial compared with all other phases. Investigator-initiated trials saw the highest proportion of PPSIs per trial (0.44:1) of all sponsor types. Conclusions: This study demonstrates a gap in patient safety when assessing trial documents for clinical trial implementation. One solution to address this gap is the utilization of a centralized team of clinical specialists to preemptively review trial documents, thereby enhancing patient safety during clinical trial conduct.
- Open Access
- 18 April 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-5
The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study
This study reports the incidence of chronic graft versus host disease (GvHD) in allogeneic hematopoietic stem cell transplant (alloHCT) recipients who received SARS-CoV2 vaccination. The overall rates of new and worsening chronic GvHD combined were 14%, with median time from vaccination to GVHD being approximately three to four weeks. A majority of the cases were of mild to moderate severity and primarily localized to either the skin, mouth, or joints. Prior chronic GVHD and recent transplant were associated with higher GVHD rates following COVID-19 vaccination. More prospective studies are needed to provide a definitive mechanism for the impact of SARS-CoV2 vaccination on alloHCT patients.
- 18 April 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-5
Open AccessThe impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study
This study reports the incidence of chronic graft versus host disease (GvHD) in allogeneic hematopoietic stem cell transplant (alloHCT) recipients who received SARS-CoV2 vaccination. The overall rates of new and worsening chronic GvHD combined were 14%, with median time from vaccination to GVHD being approximately three to four weeks. A majority of the cases were of mild to moderate severity and primarily localized to either the skin, mouth, or joints. Prior chronic GVHD and recent transplant were associated with higher GVHD rates following COVID-19 vaccination. More prospective studies are needed to provide a definitive mechanism for the impact of SARS-CoV2 vaccination on alloHCT patients.
- Open Access
- 14 May 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 349-354
A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant
- 14 May 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 349-354
Open AccessA Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant
- 1 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (3) , 157-160
Biosimilar Impact on Oncology Clinical Trial Design and Operations
- 1 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (3) , 157-160
Biosimilar Impact on Oncology Clinical Trial Design and Operations
- 9 June 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (10) , 2464-2470
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation
Currently, there is no consensus on best practices to prevent hemorrhagic cystitis (HC) in patients receiving posttransplant cyclophosphamide (PTCy). We retrospectively reviewed 194 patients undergoing their first hematopoietic cell transplant (HCT) who received PTCy from 2014 to 2018 to describe the incidence and severity of HC, identify potential risk factors, and impact of HC on HCT outcomes. Standard HC prophylaxis was hyperhydration with forced diuresis and mesna at 320% the daily dose of PTCy. Incidence of HC was 31.4% at day +100 of HCT. Median onset of HC was 12 days with 11.5% grade 3 HC and no Grade 4 HC. Patients with chemical HC experienced earlier onset (7 days vs. 34 days, p < 0.001) with a shorter median resolution time (5 days vs. 14 days, p = 0.001) when compared to BK-associated HC. In multivariate analysis, age above 60 years (HR 4.16, p = 0.006) and myeloablative conditioning (HR 2.44, p = 0.054) were associated with higher risk for HC, but overall, HC did not affect nonrelapse mortality or overall survival. In conclusion, hyperhydration with forced diuresis combined with aggressive mesna dosing is an effective strategy in preventing severe PTCy-associated HC, subsequently preventing any negative impact on transplant outcome.
- 9 June 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (10) , 2464-2470
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation
Currently, there is no consensus on best practices to prevent hemorrhagic cystitis (HC) in patients receiving posttransplant cyclophosphamide (PTCy). We retrospectively reviewed 194 patients undergoing their first hematopoietic cell transplant (HCT) who received PTCy from 2014 to 2018 to describe the incidence and severity of HC, identify potential risk factors, and impact of HC on HCT outcomes. Standard HC prophylaxis was hyperhydration with forced diuresis and mesna at 320% the daily dose of PTCy. Incidence of HC was 31.4% at day +100 of HCT. Median onset of HC was 12 days with 11.5% grade 3 HC and no Grade 4 HC. Patients with chemical HC experienced earlier onset (7 days vs. 34 days, p < 0.001) with a shorter median resolution time (5 days vs. 14 days, p = 0.001) when compared to BK-associated HC. In multivariate analysis, age above 60 years (HR 4.16, p = 0.006) and myeloablative conditioning (HR 2.44, p = 0.054) were associated with higher risk for HC, but overall, HC did not affect nonrelapse mortality or overall survival. In conclusion, hyperhydration with forced diuresis combined with aggressive mesna dosing is an effective strategy in preventing severe PTCy-associated HC, subsequently preventing any negative impact on transplant outcome.